1. SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant
- Author
-
Guo, Hongchao, Yu, Xuan, Liu, Yu, Paik, David T, Justesen, Johanne Marie, Chandy, Mark, Jahng, James WS, Zhang, Tiejun, Wu, Weijun, Rwere, Freeborn, Zhao, Shane Rui, Pokhrel, Suman, Shivnaraine, Rabindra V, Mukherjee, Souhrid, Simon, Daniel J, Manhas, Amit, Zhang, Angela, Chen, Che-Hong, Rivas, Manuel A, Gross, Eric R, Mochly-Rosen, Daria, and Wu, Joseph C
- Subjects
Pharmacology and Pharmaceutical Sciences ,Biomedical and Clinical Sciences ,Prevention ,Stem Cell Research - Induced Pluripotent Stem Cell - Human ,Substance Misuse ,Heart Disease ,Genetics ,Stem Cell Research - Induced Pluripotent Stem Cell ,Cardiovascular ,Stem Cell Research ,Clinical Research ,Pediatric ,Alcoholism ,Alcohol Use and Health ,Heart Disease - Coronary Heart Disease ,Atherosclerosis ,2.1 Biological and endogenous factors ,Good Health and Well Being ,Humans ,Mice ,Animals ,Aldehyde Dehydrogenase ,Mitochondrial ,Sodium-Glucose Transporter 2 Inhibitors ,Genome-Wide Association Study ,Induced Pluripotent Stem Cells ,Coronary Artery Disease ,Aldehyde Dehydrogenase ,Biological Sciences ,Medical and Health Sciences ,Medical biotechnology ,Biomedical engineering - Abstract
The common aldehyde dehydrogenase 2 (ALDH2) alcohol flushing variant known as ALDH2*2 affects ∼8% of the world's population. Even in heterozygous carriers, this missense variant leads to a severe loss of ALDH2 enzymatic activity and has been linked to an increased risk of coronary artery disease (CAD). Endothelial cell (EC) dysfunction plays a determining role in all stages of CAD pathogenesis, including early-onset CAD. However, the contribution of ALDH2*2 to EC dysfunction and its relation to CAD are not fully understood. In a large genome-wide association study (GWAS) from Biobank Japan, ALDH2*2 was found to be one of the strongest single-nucleotide polymorphisms associated with CAD. Clinical assessment of endothelial function showed that human participants carrying ALDH2*2 exhibited impaired vasodilation after light alcohol drinking. Using human induced pluripotent stem cell-derived ECs (iPSC-ECs) and CRISPR-Cas9-corrected ALDH2*2 iPSC-ECs, we modeled ALDH2*2-induced EC dysfunction in vitro, demonstrating an increase in oxidative stress and inflammatory markers and a decrease in nitric oxide (NO) production and tube formation capacity, which was further exacerbated by ethanol exposure. We subsequently found that sodium-glucose cotransporter 2 inhibitors (SGLT2i) such as empagliflozin mitigated ALDH2*2-associated EC dysfunction. Studies in ALDH2*2 knock-in mice further demonstrated that empagliflozin attenuated ALDH2*2-mediated vascular dysfunction in vivo. Mechanistically, empagliflozin inhibited Na+/H+-exchanger 1 (NHE-1) and activated AKT kinase and endothelial NO synthase (eNOS) pathways to ameliorate ALDH2*2-induced EC dysfunction. Together, our results suggest that ALDH2*2 induces EC dysfunction and that SGLT2i may potentially be used as a preventative measure against CAD for ALDH2*2 carriers.
- Published
- 2023